Prezista

 

Topic mentions per year

Topic mentions per year

2006-2013
012320062013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
s?&vmview=abst_detail_view&confID=1 33&abstractID=106143 Janssen Therapeutics (NJ, USA) has recently announced the US FDA… (More)
Is this relevant?
2010
2010
OBJECTIVE To investigate the potential for a pharmacokinetic interaction between darunavir (DRV, TMC114, Prezista), indinavir… (More)
Is this relevant?
Review
2008
Review
2008
 
Is this relevant?
2007
2007
BACKGROUND This open-label, crossover study investigated the pharmacokinetic interaction between TMC114 (darunavir [Prezista… (More)
Is this relevant?
2007
2007
Darunavir (DRV; TMC114; Prezista) is a human immunodeficiency virus (HIV) protease inhibitor used in combination with low-dose… (More)
Is this relevant?
Review
2007
Review
2007
On 3 previous occasions, in 2002, 2003 and 2005, the Swedish Medical Products Agency (Läkemedelsverket) and the Swedish Reference… (More)
Is this relevant?
2007
2007
  • AIDS patient care and STDs
  • 2007
 
Is this relevant?
2006
2006
  • The Medical letter on drugs and therapeutics
  • 2006
Darunavir (Prezista--Tibotec), a new protease inhibitor, has received accelerated approval from the FDA for use in combination… (More)
Is this relevant?
2006
2006
A major new antiretroviral has been approved, for patients resistant to more than one protease inhibitor. There is no information… (More)
Is this relevant?
Review
2006
Review
2006
Despite landmark achievements (e.g. >20 new anti-HIV drugs), a number of important therapeutic challenges remain. Although an… (More)
Is this relevant?